Effects of sitagliptin on exercise capacity and hemodynamics in patients with type 2 diabetes mellitus and coronary artery disease
| Autor: | Toshiki Sawai, Naoki Fujimoto, Naoto Kumagai, Shiro Nakamori, Jun Masuda, Masaaki Ito, Kaoru Dohi, Tetsushiro Takeuchi, Keishi Moriwaki, Yuichi Sato |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Hemodynamics Coronary Artery Disease 030204 cardiovascular system & hematology Ventricular Function Left Coronary artery disease 03 medical and health sciences 0302 clinical medicine Japan Internal medicine Voglibose Heart rate Medicine Humans Glycoside Hydrolase Inhibitors 030212 general & internal medicine Prospective Studies Reactive hyperemia Aged Dipeptidyl-Peptidase IV Inhibitors Exercise Tolerance business.industry Sitagliptin Phosphate Recovery of Function Middle Aged medicine.disease Blood pressure Treatment Outcome Diabetes Mellitus Type 2 Sitagliptin Cardiology Female Cardiology and Cardiovascular Medicine business Anaerobic exercise Inositol medicine.drug |
| Zdroj: | Heart and vessels. 35(5) |
| ISSN: | 1615-2573 |
| Popis: | Sitagliptin attenuates left ventricular (LV) dysfunction and may improve oxygen uptake in animals. The effects of sitagliptin on oxygen uptake (VO2) and exercise hemodynamics have been unclear in patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). Thirty patients with T2DM and CAD were randomized into a sitagliptin (50 mg/day) or voglibose (0.6 mg/day) group. Patients underwent maximal cardiopulmonary exercise testing. VO2 and hemodynamics were evaluated at rest, anaerobic threshold and peak exercise. Resting LV diastolic function (E’, peak early diastolic mitral annular velocity) and geometry were evaluated by echocardiography, and endothelial function by reactive hyperemia peripheral arterial tonometry. A total of 24 patients (69 ± 9 years) completed 6 months of intervention. Peak VO2 in the sitagliptin and voglibose groups (25.3 ± 7.3 vs. 24.0 ± 7.4, 22.7 ± 4.8 vs. 22.1 ± 5.2 ml/kg/min) was slightly decreased after 6 months (time effect p = 0.051; group × time effect p = 0.49). No effects were observed on LV ejection fraction, E’, or reactive hyperemia index in either group. Heart rate during exercise was unaffected in both groups. Systolic blood pressure was unchanged by sitagliptin at rest and during exercise, but slightly lowered by voglibose at anaerobic threshold and peak exercise. In patients with T2DM and CAD, sitagliptin had little effect on resting LV and arterial function, exercise capacity, or exercise hemodynamics. Further studies need to be conducted with more patients as the number of the patients in this study was limited. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink